XML 21 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 6 Months Ended 12 Months Ended
Dec. 31, 2020
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (53.1) $ (199.5) $ 4.6 $ 133.3
Adjustments to reconcile net income (loss) to net cash provided by operating activities:        
Depreciation and amortization 35.8 72.0 73.0 54.4
Non-cash interest expense 0.4 0.5 0.4 0.2
Non-cash lease expense 6.4 0.0 0.0 0.0
Gain on deconsolidation of subsidiary 0.0 (1.0) 0.0 0.0
Non-cash impact of foreign currency transactions (1.0) 0.0 0.0 0.0
Gain on disposition of assets (0.1) 0.0 (0.9) (0.2)
Share-based compensation expense 14.9 25.2 33.5 27.1
Deferred income taxes 44.2 (55.8) 18.6 (23.5)
Unrecognized tax benefits 7.1 1.7 (5.5) (0.3)
Impairment of goodwill and intangible assets 0.0 99.7 0.0 0.0
Change in fair value of contingent consideration 3.5 2.8 (1.4) (60.9)
Payment of contingent consideration 0.0 0.0 (1.5) (22.7)
Changes in assets and liabilities:        
Prepaid expenses 2.1 2.2 (3.2) 3.3
Trade accounts receivable (21.4) 64.0 (18.2) (9.1)
Other receivables 1.0 0.6 (0.7) 1.1
Inventory 2.2 1.6 8.0 7.9
Prepaid taxes (108.4) 25.1 (25.1) 0.0
Other assets (2.3) 0.0 0.0 0.0
Accounts payable (1.2) (10.7) 1.1 4.0
Accrued liabilities (3.6) 1.6 1.5 1.4
Deferred revenue (0.2) 30.7 (0.5) (0.1)
Net cash provided by (used in) operating activities (73.7) 60.7 83.7 115.9
CASH FLOWS FROM INVESTING ACTIVITIES:        
Capital expenditures (7.9) (10.2) (8.6) (8.4)
Acquisitions, net of cash acquired 0.0 0.0 (278.5) 0.0
Proceeds from sale of subsidiary 0.0 21.3 0.0 0.0
Purchases of marketable investment securities 0.0 (60.8) (78.5) (80.9)
Proceeds from maturities and sales of marketable investment securities 35.9 69.0 79.2 77.7
Net cash provided by (used in) investing activities 28.0 19.3 (286.4) (11.6)
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from common stock issued under share-based compensation plans 1.8 13.3 23.2 45.3
Payment of tax withheld for common stock issued under share-based compensation plans (3.8) (9.8) (14.5) (8.4)
Proceeds from revolving credit facility 0.0 0.0 340.0 53.0
Repayment of revolving credit facility 0.0 (8.6) (115.0) (143.0)
Payment of contingent consideration recognized at acquisition (0.1) (3.9) 0.0 (42.4)
Fees associated with refinancing of revolving credit facility 0.0 (1.0) (1.4) 0.0
Repurchase and retirement of common stock 0.0 0.0 (50.0) 0.0
Proceeds from non-controlling interest 0.0 0.0 0.0 0.5
Net cash provided by (used in) financing activities (2.1) (10.0) 182.3 (95.0)
Effect of foreign exchange rates on cash and cash equivalents 1.1 0.5 2.7 (0.8)
Net increase (decrease) in cash and cash equivalents (46.7) 70.5 (17.7) 8.5
Cash and cash equivalents at beginning of year 163.7 93.2 110.9 102.4
Cash and cash equivalents at end of year $ 117.0 $ 163.7 $ 93.2 $ 110.9